Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.

[1]  C. Waters,et al.  Compulsive eating and weight gain related to dopamine agonist use , 2006, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Cussac,et al.  Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. , 2006, European journal of pharmacology.

[3]  Graeme Milligan,et al.  Techniques: promiscuous Galpha proteins in basic research and drug discovery. , 2005, Trends in pharmacological sciences.

[4]  Lauterbach Ec.  The neuropsychiatry of Parkinson's disease. , 2005, Minerva medica.

[5]  Toyoki Mori,et al.  Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. , 2005, European journal of pharmacology.

[6]  G. Reynolds.  Receptor Mechanisms in the treatment of Schizophrenia , 2004, Journal of psychopharmacology.

[7]  R. Mailman,et al.  Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. , 2004, Molecular pharmacology.

[8]  M. Millan,et al.  S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.

[9]  B. Dean,et al.  Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. , 2004, Current drug targets. CNS and neurological disorders.

[10]  P. Strange,et al.  Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. , 2004, Biochemical pharmacology.

[11]  P. Strange,et al.  Constitutive oligomerization of human D2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9) and in HEK293 cells. Analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer. , 2003, European journal of biochemistry.

[12]  P. Pauwels,et al.  Pharmacological analysis of a dopamine D2Short:Gαo fusion protein expressed in Sf9 cells , 2003 .

[13]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[14]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[15]  Q. Shan,et al.  The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling. , 2002, Biochemical and biophysical research communications.

[16]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[17]  C. Tamminga,et al.  Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. , 2002, Current drug targets. CNS and neurological disorders.

[18]  C. Tamminga,et al.  Partial dopamine agonists in the treatment of psychosis , 2002, Journal of Neural Transmission.

[19]  S. Stahl.  Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. , 2001, The Journal of clinical psychiatry.

[20]  S. Nickolls,et al.  Agonist Regulation of D2 Dopamine Receptor/G Protein Interaction , 2001, The Journal of Biological Chemistry.

[21]  Y. Nakata,et al.  Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. , 2001, Japanese journal of pharmacology.

[22]  K. Fuxe,et al.  Modulation of [35S]GTPγS binding to Chinese hamster ovary cell membranes by D2(short) dopamine receptors , 2000, Neuroscience Letters.

[23]  J. Kulisevsky.  [New treatments in movement disorders]. , 1999, Neurologia.

[24]  J. Leysen,et al.  Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[26]  S. George,et al.  Functional analysis of the D2L dopamine receptor expressed in a cAMP-responsive luciferase reporter cell line. , 1998, Biochemical pharmacology.

[27]  K. Marquis,et al.  New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. , 1997, Journal of medicinal chemistry.

[28]  P. Strange,et al.  Agonist Action at D2(short) Dopamine Receptors Determined in Ligand Binding and Functional Assays , 1997, Journal of neurochemistry.

[29]  H. Ueda,et al.  Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. , 1997, European journal of pharmacology.

[30]  H. Wetzel,et al.  Dopamine agonists in schizophrenia: a review , 1995, European Neuropsychopharmacology.

[31]  E. Borrelli,et al.  Alternative Splicing of the Dopamine D2 Receptor Directs Specificity of Coupling to G-proteins (*) , 1995, The Journal of Biological Chemistry.

[32]  E. Borrelli,et al.  Preferential coupling between dopamine D2 receptors and G-proteins. , 1993, Molecular endocrinology.

[33]  D. Evans,et al.  Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. , 1992, Molecular pharmacology.

[34]  A. Friedhoff,et al.  Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. , 1986, European journal of pharmacology.

[35]  P. B. Silverman,et al.  Persistent behavioural effect of apomorphine in 6-hydroxydopamine-lesioned rats , 1981, Nature.

[36]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[37]  H. Fibiger,et al.  Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions ofd-amphetamine and apomorphine , 2005, Psychopharmacology.

[38]  S. Iversen,et al.  Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra , 2004, Psychopharmacology.

[39]  J. Lieberman.  Dopamine Partial Agonists , 2004, CNS drugs.

[40]  Y. Itoyama,et al.  Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats , 2000, Journal of Neural Transmission.

[41]  D. Coward,et al.  Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. , 1990, The Journal of pharmacology and experimental therapeutics.